Third Rock Ventures has led a series A round for Abata Therapeutics, launched by the firm to commercialise research from Harvard, MIT, Johns Hopkins, NIH and UZH.

Abata Therapeutics, a US-based cell therapy developer focused on autoimmune and inflammatory diseases, has launched with $95m in series A financing led by Third Rock Ventures to advance research from multiple institutions.
Gene and cell therapy developer ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital and the JDRF T1D Fund participated in the round, which followed an undisclosed amount of seed capital supplied by Third Rock and ElevateBio at an unspecified date.
Abata Therapeutics is working on translating the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in